Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 160 participants.

Also called NCT06417489

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06417489
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06417489. Randomized; no masking; primary purpose treatment. Start 2024-05-31 (anticipated); primary completion 2026-05-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients
Intervention (Drug)
Combination therapy
Intervention (Drug)
Sequential treatment group
Lead sponsor
Peking University First Hospital (class: other)

Record details

Record id
cardio:ct-nct06417489
Content hash
7ecf55fedc42f437c142bdf1bc911705166b065e88bb855775b424a1ebd2bf59